{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:49Z","timestamp":1792800889647,"version":"4.5.0"},"reference-count":19,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have become an increasingly prominent therapeutic option in the management of a variety of cancers. As their clinical use expands, so too should our understanding of immune-related adverse events (irAEs) associated with these agents. By enhancing immune activation, ICIs can cause off-target inflammation in various tissues, including endocrine. We present a case illustrating a rare but life-threatening manifestation of ICI toxicity: simultaneous severe diabetes mellitus and thyrotoxicosis after just a single dose of ICI. This case highlights the importance of prompt recognition and timely intervention of acute, life-threatening endocrine irAEs. We discuss the pathophysiology, management, and clinical course of ICI-induced diabetes mellitus and thyroid disease, with brief discussion of endocrine irAEs as a surrogate of therapeutic efficacy.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag241","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:02:56Z","timestamp":1790769776000},"source":"Crossref","is-referenced-by-count":1,"title":["Simultaneous immune checkpoint blockade-associated diabetes mellitus and thyrotoxicosis"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1250-1254","authenticated-orcid":false,"given":"Miranda","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Franke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0285-6622","authenticated-orcid":false,"given":"Yogish C","family":"Kudva","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, & Nutrition, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"1","key":"2026100422265628800_luag241-B1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"key":"2026100422265628800_luag241-B2","doi-asserted-by":"crossref","first-page":"e14613","DOI":"10.1200\/JCO.2024.42.16_suppl.e14613","article-title":"Updated estimates of eligibility and response: immune checkpoint inhibitors","volume":"42","author":"Prasad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026100422265628800_luag241-B3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus","volume":"87","author":"Kani","year":"2025","journal-title":"Endocrine"},{"issue":"16","key":"2026100422265628800_luag241-B4","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2022.40.16_suppl.2654","article-title":"Immune-related adverse events and immunotherapy efficacy in patients with cancer: a retrospective study","volume":"40","author":"Prather","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026100422265628800_luag241-B5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/clinem\/dgad685","article-title":"Checkpoint inhibitor-associated autoimmune diabetes Mellitus is characterized by C-peptide loss and pancreatic atrophy","volume":"109","author":"Wu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026100422265628800_luag241-B6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"2026100422265628800_luag241-B7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026100422265628800_luag241-B8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"2026100422265628800_luag241-B9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026100422265628800_luag241-B10","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes Mellitus (CIADM): a systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"2026100422265628800_luag241-B11","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"10","key":"2026100422265628800_luag241-B12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor-induced diabetes","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026100422265628800_luag241-B13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"36","key":"2026100422265628800_luag241-B14","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026100422265628800_luag241-B15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1530\/EC-18-0082","article-title":"Clinical diagnosis of graves\u2019 or non-graves\u2019 hyperthyroidism compared to TSH receptor antibody test","volume":"7","author":"Bell","year":"2018","journal-title":"Endocr Connect"},{"issue":"6","key":"2026100422265628800_luag241-B16","first-page":"417","article-title":"[Graves disease with negative TSH receptor antibodies: a presentation of 5 cases]","volume":"93","author":"Scatti Regas","year":"2020","journal-title":"An Pediatr (Engl Ed)"},{"key":"2026100422265628800_luag241-B17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.749064","article-title":"Immune-related adverse events in PD-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis","volume":"11","author":"Bastacky","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"2026100422265628800_luag241-B18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 Inhibitor-Induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"2","key":"2026100422265628800_luag241-B19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag241\/71579333\/luag241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/11\/luag241\/71579333\/luag241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:27:07Z","timestamp":1791167227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag241\/8860419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag241","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,25]]},"article-number":"luag241"}}